Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2011-06-28
2011-06-28
Ghali, Isis A (Department: 1611)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S465000, C424S451000, C424S490000, C424S491000, C424S488000, C424S489000
Reexamination Certificate
active
07968119
ABSTRACT:
A composition for oral, transdermal or subdermal administration to a subject is described. The composition contains: (a) an agonist component; (b) an antagonist component containing at least one antagonist and having a delayed time of release; and (c) an immediate release antagonist removal component, where the subject includes a gastrointestinal tract and the antagonist removal component is present in an amount sufficient to substantially remove the antagonist component from the gastrointestinal tract of the subject before the time of release of the antagonist component. The composition may be delivered to the subject by a method which includes the step of administering the composition orally, transdermally or subdermally to the subject. When the composition of the present invention is administered orally, the method of the present invention may include the step of administering a potassium compound to the subject.
REFERENCES:
patent: 3493657 (1970-02-01), Lewenstein et al.
patent: 3773955 (1973-11-01), Pachter
patent: 3896226 (1975-07-01), Fishman
patent: 4391797 (1983-07-01), Folkman et al.
patent: 4457933 (1984-07-01), Gordon et al.
patent: 4582835 (1986-04-01), Lewis et al.
patent: 4906463 (1990-03-01), Cleary et al.
patent: 4987136 (1991-01-01), Kreek et al.
patent: 5317022 (1994-05-01), Borsodi et al.
patent: 5494677 (1996-02-01), Giampapa
patent: 5496561 (1996-03-01), Okada et al.
patent: 5512587 (1996-04-01), Spector
patent: 5518730 (1996-05-01), Fuisz
patent: 5540912 (1996-07-01), Roorda et al.
patent: 5569467 (1996-10-01), Ruiz
patent: 5580569 (1996-12-01), Giampapa
patent: 5609886 (1997-03-01), Wantier et al.
patent: 5679373 (1997-10-01), Wick et al.
patent: 5698217 (1997-12-01), Wilking
patent: 5709883 (1998-01-01), Drizen et al.
patent: 5716631 (1998-02-01), Drizen et al.
patent: 5780589 (1998-07-01), Lazarus et al.
patent: 5783583 (1998-07-01), Simon
patent: 5792477 (1998-08-01), Rickey et al.
patent: 5811451 (1998-09-01), Minoia et al.
patent: 5820877 (1998-10-01), Yamaguchi et al.
patent: 5834477 (1998-11-01), Mioduszewski
patent: 5840332 (1998-11-01), Lerner et al.
patent: 5855915 (1999-01-01), Pinkus
patent: 5885486 (1999-03-01), Westesen et al.
patent: 5919473 (1999-07-01), Elkhoury
patent: 5922705 (1999-07-01), Simon
patent: 5958452 (1999-09-01), Oshlack et al.
patent: 5958455 (1999-09-01), Roser et al.
patent: 5972954 (1999-10-01), Foss et al.
patent: 6013280 (2000-01-01), Frisbee et al.
patent: 6020002 (2000-02-01), Myers et al.
patent: 6066339 (2000-05-01), Stark et al.
patent: 6068855 (2000-05-01), Leslie et al.
patent: 6130258 (2000-10-01), Bellos
patent: 6132416 (2000-10-01), Broselow
patent: 6214379 (2001-04-01), Hermelin
patent: 6217911 (2001-04-01), Vaugn et al.
patent: 6228863 (2001-05-01), Palermo et al.
patent: 6231886 (2001-05-01), Reder et al.
patent: 6261599 (2001-07-01), Oshlack et al.
patent: 6277384 (2001-08-01), Kaiko et al.
patent: 6310072 (2001-10-01), Smith et al.
patent: 6326027 (2001-12-01), Miller et al.
patent: 6335033 (2002-01-01), Oshlack et al.
patent: 6375957 (2002-04-01), Kaiko et al.
patent: 6696088 (2004-02-01), Oshlack et al.
patent: 2002/0010127 (2002-01-01), Oshlack et al.
patent: 2002/0058673 (2002-05-01), Kaiko et al.
patent: 2003/0124185 (2003-07-01), Oshlack et al.
patent: 2282205 (1993-03-01), None
patent: WO0185257 (2001-11-01), None
“The management of constipation”, National Prescribing Centre, vol. 10, No. 9, 1999.
“Laxative-induced hypokalemic myopathy. A case history”. Vierhapper et al.. Weinklin Wochenschr. Feb. 1, 1980; 92 (3): 101-3.
Full document of the article “Laxative-induced hypokalemic myopathy. A case history”. Vierhapper et al.. Weinklin Wochenschr. Feb. 1, 1980; 92 (3): 101-3.
Mason, Barbara J., PhD, Salvato, Fernando R., MD; Williams, Lauren D., MD; Ritvo, Eva C., MD; Cutler, Robert B., PhD, “A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence”, Arch Gen Psychiatry, vol. 56, Aug. 1999, pp. 719-724.
Pasternak, Gavril W., “Pharmacological Mechanisms of Opioid Analgesics”,Clinical Neuropharmacology, vol. 16, No. 1, pp. 1-18, 1993.
Yuan, Chun-Su, MD, PhD., Foss, Joseph F., MD; O'Connor, Michael, MD; Osinski, Joachim MS; Karrison, Theodore, PhD.; Jonathan Moss, MD, PhD; Roizen, Michael F., MD; “Methylnaltrexone for Reversal of Constipation Due to Chronic Methadone Use”, JAMA, Jan. 19, 2000, vol. 283, No. 3, p. 367.
Carpenter, Randall L., MD; Kurz, Andrea, MD; Saleem, Rao M., MD; Sessler, Daniel I., MD; Seyedsadr, Mahmoud, PhD; Sharma, Neeru MD; and Taguchi Akiko, MD, “Selective Postoperative Inhibition of Gastrointestinal Opioid Receptors”, The New England Journal of Medicine, vol. 345, No. 13, Sep. 27, 2001, p. 935.
Barr, W.H., PharmD, PhD; Carpenter, RL., MD; Nguyen, P., Russell, R., Slattery, M., Virginia Commonwealth University, Center for Drug Studies, Richmond, VA, and Adolor Corp., Malvern, PA, “ADL 8-2698 Reverses Opioid Induced Delay in Colonic Transit”, American Society for Clinical Pharmacology and Therapeutics, vol. 67, No. 2, p. 91.
Joshi, G. P., Duffy, L., Chehade, J., Wesevich, J., Gajraj, N., Johnson, E. R., “Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia,” Anesthesiology, vol. 90, 1999, pp. 1007-1011.
Culpepper-Morgan, J. A., Inturrisi, C. E., Portenoy, R. K., Foley, K., Houde, R. W., Marsh, F., Kreek, M. J., “Treatment of opioid-induced constipation with oral naloxone.”.
Yuan, Chun-Su, MD, PhD., Foss, Joseph F., MD; O'Connor, Michael, MD; Toledano, Alicia, ScD, Roizen, Michael F., MD; and Jonathan Moss, MD, PhD; “Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double blind randomized placebo-controlled trial.”(Cpin, Pharmacol. Ther. 1996; 59: 469-75).
LandOfFree
Tamper-proof narcotic delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tamper-proof narcotic delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tamper-proof narcotic delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2679900